PA32540 + clopidogrel

PA32540 + clopidogrel is a **combination therapy** involving a proprietary tablet (PA32540) and clopidogrel, administered sequentially, primarily for patients requiring dual antiplatelet therapy with high risk of gastrointestinal complications. PA32540 itself is a fixed-dose combination of **enteric-coated aspirin (325 mg)** and **immediate-release omeprazole (40 mg)**, designed to reduce upper gastrointestinal injury and symptoms associated with aspirin therapy, while maintaining cardiovascular protective efficacy. Clopidogrel is a thienopyridine antiplatelet agent that inhibits ADP-induced platelet aggregation. This regimen has shown enhanced antiplatelet activity when the PA32540 tablet and clopidogrel are spaced 10 hours apart compared to synchronous administration, without loss of gastroprotection[1][2][3][4][6].

Brand names

Plavix + PA32540

Other names

PA32540 + clopidogrel